All In Biotech

Drug Trial Radar · NCT00419341

Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy

A Phase III Open-Label, Prospective, Multicenter Study of the Efficacy, Tolerability, Safety, and Pharmacokinetics of Immune Globulin Subcutaneous (Human), IgPro20 in Subjects With Primary Immunodeficiency (PID)

Last checked: Nov 19, 2026Latest source record: Jan 25, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

49

Actual

Start

Nov 2006

Primary completion

Oct 2008

Study completion Oct 2008

Sponsor

Lead sponsor
CSL BehringIndustry
Sponsor type
Industry
First posted
Jan 8, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 2 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to assess the efficacy, tolerability, safety and pharmacokinetics of IgPro20 in patients with primary humoral immunodeficiency (PID).

Conditions

  • Primary Immune Deficiency

Interventions

  • Human Normal Immunoglobulin for Subcutaneous AdministrationBiological

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Rate of Clinically Documented Serious Bacterial Infections (SBIs) (MITT Population)Time frame: Efficacy period: up to 12 months (week 13 to the completion visit)
  2. Area Under the Concentration-time Curve (AUC) of Total Serum Immunoglobulin G (IgG)Time frame: Measured during a single dosing interval after at least 12 weeks of stable subcutaneous (SC) dosing with IgPro20 treatment

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Study Site

    Los Angeles, California

  • Study Site

    Los Angeles, California

  • Study Site

    Centennial, Colorado

  • Study Site

    North Palm Beach, Florida

  • Study Site

    Atlanta, Georgia

  • Study Site

    Fort Wayne, Indiana

  • Study Site

    Indianapolis, Indiana

  • Study Site

    Iowa City, Iowa

  • Study Site

    St Louis, Missouri

  • Study Site

    Newark, New Jersey

  • Study Site

    New York, New York

  • Study Site

    Philadelphia, Pennsylvania

  • Study Site

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.